Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation therapy. Products are sold to home-care, institutional and government markets in the United States and internationally. This unaudited report covers the three and six months ended December 31, 2013, the company’s fiscal second quarter and first half of fiscal 2014. The company had 8,114,252 common shares outstanding as of February 7, 2014.
Financial Performance and Position
| Metric | Three Months Ended Dec. 31, 2013 | Three Months Ended Dec. 31, 2012 | Six Months Ended Dec. 31, 2013 | Six Months Ended Dec. 31, 2012 |
|---|---|---|---|---|
| Net revenue | $3.501 million | $3.856 million | $6.919 million | $7.888 million |
| Gross profit | $2.523 million | $2.514 million | $4.879 million | $5.335 million |
| Gross margin | 72.1% | 65.2% | 70.5% | 67.6% |
| Operating loss | $0.309 million | $0.595 million | $0.886 million | $0.692 million |
| Net loss | $0.239 million | $0.411 million | $0.575 million | $0.482 million |
| Loss per share | $0.03 | $0.05 | $0.07 | $0.06 |
| Cash provided by operating activities | Approximately $0.390 million | Not clearly provided | $1.132 million | $1.202 million |
Six-month revenue declined 12.3%, while the company remained unprofitable. The second-quarter net loss narrowed because of improved gross margin and lower professional and legal expenses. The six-month net loss increased because the revenue decline more than offset expense reductions.
At December 31, 2013, cash and cash equivalents were $1.237 million, compared with $0.504 million at June 30, 2013. Working capital was approximately $10 million. Total assets were $17.398 million and total equity was $13.418 million. Total debt, including current maturities, was approximately $1.320 million.
Accounts receivable declined to $7.041 million from $9.014 million at June 30, 2013, while inventory increased to $2.267 million from $1.380 million, principally in preparation for the new SmartVest SQL launch. The warranty reserve was $0.700 million.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue decreased 9.2%; six-month revenue decreased 12.3%.
- Home-care revenue fell 11.8% in the quarter and 16.3% for the six-month period, driven by lower average selling prices, fewer referrals and slower third-party payer approvals.
- International revenue decreased 35.5% in the quarter and 12.2% year to date, partly reflecting distributor-purchase timing and weaker Asian sales.
- Government and institutional revenue increased 36.6% in the quarter and 29.0% year to date.
- Gross margin improved to 72.1% in the quarter and 70.5% year to date, primarily from manufacturing-cost leverage while building SQL inventory.
- Second-quarter SG&A decreased 8.7%; six-month SG&A decreased 6.1%. Professional fees declined because prior-year consulting expenses and shareholder-related litigation costs did not recur at the same level.
- Six-month research and development expense increased 43.8% to $302,000 as the company finalized development and testing of the SmartVest SQL.
- Operating cash flow remained positive but declined to $1.132 million from $1.202 million, while investing cash use declined to $293,000 from $510,000.
Guidance, Outlook, Risks and Unusual Items
On December 30, 2013, the FDA cleared the SmartVest SQL, which is lighter, quieter and smaller and includes new user features. The company began selling it in the domestic home-care market in January 2014, but expects limited near-term revenue impact because reimbursement approvals take time.
Management expects long-term gross margins of approximately 70% and research and development spending of approximately 3% to 5% of revenue. Growth initiatives include marketing the SQL, expanding international distribution and strengthening the institutional sales effort. No formal revenue or earnings guidance was provided.
Third-party payer reimbursement remains a material risk. Pricing pressure, additional claims procedures and incomplete contracting with certain Blue Cross and Blue Shield affiliates have reduced referrals and lengthened approval times. Continued operating losses or weaker taxable income could require a valuation allowance against deferred tax assets.
On December 18, 2013, the company replaced its U.S. Bank facility with a Venture Bank facility comprising a $2.5 million revolving line of credit and a $1.3 million term loan. The revolver had no outstanding balance at December 31, 2013 and expires December 18, 2014 unless renewed. The facility requires minimum tangible net worth of $12 million and includes other debt and dividend restrictions. Borrowings are secured by substantially all tangible and intangible assets, and the term loan is secured by company real property.
Management believes current working capital and available borrowing capacity will support the next year, but cautions that covenant violations, non-renewal of the revolver or unfavorable refinancing could result in accelerated debt repayment, loss of financing access or inability to continue operations as planned. A shareholder-related litigation matter was settled in the first quarter of fiscal 2014; the company expects most related costs to be covered by insurance, but coverage is not guaranteed. The filing reports no material undisclosed litigation, no off-balance-sheet arrangements and effective disclosure controls.
Key Facts for Investor Verification
- Verify whether home-care referrals, reimbursement approvals, pricing and payer contracting improved after December 31, 2013.
- Assess the SmartVest SQL’s commercial adoption, reimbursement timing and effect on revenue, margins and inventory.
- Review the Venture Bank credit agreement, covenant compliance and revolver renewal status before its December 18, 2014 expiration.
- Monitor cash generation, continued operating losses and the company’s ability to maintain its $12 million minimum tangible net worth.
- Confirm the recoverability of deferred tax assets and the adequacy of the $700,000 warranty reserve.
- Determine the final insurance recovery and remaining financial exposure related to the settled shareholder litigation.